An alternative to standard chemotherapy regimens, promising data from pre-clinical studies has been reported on the potential benefit of the administration of inhibitors of the GSK3β (iGSK3β) regulator of glucose homeostasis associated with both the control of the glycolytic pathways that are altered in PDAC and sensitization of tumor cells to gemcitabine [67] in squamous PDAC tumors that express high levels of GSK3β. The gene discussed is GSK3B; the disease is neoplasm.